Best Monoamine Oxidase Inhibitor for alzheimer disease
2 Monoamine Oxidase Inhibitor drugs used for alzheimer disease, ranked by our independent rating. Compare them with all treatments for alzheimer disease or the full Monoamine Oxidase Inhibitor class. Not medical advice — always consult a professional.
Quick answer: Of the 2 monoamine oxidase inhibitor drugs we rate for alzheimer disease, all are available as lower-cost generics, and most are patch. Our ranking reflects each drug’s FDA recall-safety record — not clinical effectiveness for alzheimer disease; the right choice depends on your situation, so confirm it with your prescriber.
Other drug classes for alzheimer disease
Top monoamine oxidase inhibitor for alzheimer disease: 1. Emsam · 2. Zelapar
| # | Drug | Rating | Type | Form | Generic? | Pharmacy pays | |
|---|---|---|---|---|---|---|---|
| 1 | Not yet rated | Prescription | Patch | Generic | $20 | View → | |
| 2 | Not yet rated | Prescription | Tablet | Generic | $20 | View → |
Full ranking · 2 drugs
emsam
PrescriptionFDA-sourced
Emsam (Selegiline) is a monoamine oxidase inhibitor used to treat Alzheimer Disease, Attention Deficit Disorder with Hyperactivity, Depressive Disorder, Parkinson Disease.
Pharmacy pays
From ~$19.44/30· 2 forms Save up to 10% in classzelapar
PrescriptionFDA-sourced
Zelapar (Selegiline Hydrochloride) is a monoamine oxidase inhibitor used to treat Alzheimer Disease, Attention Deficit Disorder with Hyperactivity, Depressive Disorder, Parkinson Disease.
Pharmacy pays
From ~$19.44/30· 2 forms Save up to 10% in classFrequently asked
- What is the best monoamine oxidase inhibitor for alzheimer disease?
- Ratings are based on FDA regulatory recall-safety data — always consult a professional.
- Which monoamine oxidase inhibitor drugs treat alzheimer disease?
- pharmaranks lists 2 Monoamine Oxidase Inhibitor products used for alzheimer disease, per NIH RxClass drug-classification data — each independently rated and ranked above.
- How are these ranked?
- By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.